Serum BLyS levels increase after rituximab as initial therapy in patients with follicular Grade 1 non-Hodgkin lymphoma.
Serum BLyS levels increase after rituximab as initial therapy in patients with follicular Grade 1 non-Hodgkin lymphoma.
复制标题
DOI：
10.1002/ajh.21328
复制
发表时间：
2009-02
影响因子：
12.8
通讯作者：
Witzig, Thomas E.
中科院分区：
文献类型：
--
作者：
Ansell, Stephen M.;Novak, Anne J.;Ziesmer, Steven;Price-Troska, Tammy;LaPlant, Betsy;Dillon, Stacey R.;Witzig, Thomas E.
血清B淋巴细胞刺激因子(BLyS)水平在部分非霍奇金淋巴瘤(NHL)患者中升高，特别是那些有B细胞恶性肿瘤家族史或BLyS基因多态性的患者。BLyS促进恶性B细胞的生长，血清BLyS水平升高与不良的临床结局相关。在这项研究中，对30例未经治疗的滤泡型1级非霍奇金淋巴瘤患者在每周4次利妥昔单抗治疗前和治疗后测定BLyS水平。利妥昔单抗治疗后血清BLyS水平显著升高(P=0.0001)。这种增加与BLyS基因的遗传变异无关。
Serum B-lymphocyte stimulator (BLyS) levels are elevated in a subset of non-Hodgkin lymphoma (NHL) patients, particularly those with a family history of B-cell malignancies or a polymorphism in the BLyS gene. BLyS promotes growth of malignant B-cells and increased serum BLyS levels are associated with a poor clinical outcome. In this study, BLyS levels were measured before and after 4 weekly doses of rituximab in 30 patients with previously untreated follicular Grade 1 NHL. A significant increase was seen in the serum levels of BLyS (P = 0.0001) after rituximab therapy. The increase was independent of genetic variability in the BLyS gene.
登录
查看更多内容
影响因子：
20.3
作者：
Colombat, P;Salles, G;Solal-Céligny, P
通讯作者：
Solal-Céligny, P
影响因子：
27.4
作者：
Lavie, Frederic;Miceli-Richard, Corinne;Mariette, Xavier
通讯作者：
Mariette, Xavier
影响因子：
20.3
作者：
Novak, AJ;Bram, RJ;Jelinek, DF
通讯作者：
Jelinek, DF
影响因子：
9.2
作者：
Marsters, SA;Yan, MH;Ashkenazi, A
通讯作者：
Ashkenazi, A
影响因子：
45.3
作者：
Novak, AJ;Grote, DM;Ansell, SM
通讯作者：
Ansell, SM